New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDS5 vs AOD-9604

DS5 vs AOD-9604

Side-by-side comparison of key properties, dosing, and research.

Sleep Optimization
DS5
Fat Loss & Metabolic
AOD-9604
Summary
DS5 is a synthetic variant of the delta sleep-inducing peptide (DSIP), a nonapeptide originally isolated from rabbit cerebrospinal fluid during slow-wave sleep. Like DSIP, DS5 is explored for sleep optimization, stress modulation, and circadian rhythm normalization, with proposed improvements in potency or stability over the parent molecule.
AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
Half-Life
Estimated 30-60 minutes (peptide degradation)
30-45 minutes injectable; longer with nasal spray formulation
Admin Route
Subcutaneous, Intranasal (research)
SubQ, Intranasal, Oral
Research
Typical Dose
200-500 mcg per dose
300-600 mcg
Frequency
Once nightly
Once daily
Key Benefits
  • Promotes delta-wave (deep) sleep and improves sleep quality
  • May reduce sleep onset latency
  • HPA axis modulation for stress reduction
  • Non-addictive sleep support without tolerance development
  • Potential circadian rhythm normalization
  • Explored for insomnia, chronic stress, and PTSD-related sleep disturbance
  • Selective fat loss without anabolic side effects
  • No effect on blood glucose or insulin resistance
  • Improved bioavailability over Fragment 176-191
  • GRAS (Generally Recognized As Safe) status in Australia
  • Potential cartilage repair and anti-inflammatory properties
  • Does not suppress natural GH production
Side Effects
  • Generally well-tolerated in research subjects
  • Possible morning grogginess at higher doses
  • Mild blood pressure fluctuations reported with DSIP
  • Limited human safety data for DS5 specifically
  • Localized injection site reactions
  • Headache (rare)
  • Hypoglycemia risk in combination with insulin (very rare)
Stacks With